» Articles » PMID: 29787011

P16INK4a As a Progression/regression Tumour Marker in LSIL Cervix Lesions: Our Clinical Experience

Overview
Date 2018 May 23
PMID 29787011
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose Of Investigation: The aim of this prospective study was the evaluation of low-grade intraepithelial lesion (LSIL) lesions evolvement in woman with evidence of high risk HPV infection and p 16 4a negative expression.

Materials And Methods: 150 women with cytological diagnosis of LSIL were selected to be underwent to three years of follow-up consisting in smear test, colposcopy, and protein p16I4a investigation every six months and HPV-test every 12 months.

Result: Final follow-up showed 45 cases of spontaneous lesion regression and 42 cases of persistence with absence of protein p164NK4a in all of them. There were three cases of disease progression to CIN2, two at 18-month follow-up and one at last follow-up. Disease progression was characterized of p16NK4a expression.

Conclusion: p16l4a should help to identify which LSIL cases are inclined to the progression of the disease and focalize which patients are eligible for specific treatment.

Citing Articles

"There is nothing that can prevent me from supporting her:" men's perspectives on their involvement and support of women's use of topical therapy for cervical precancer treatment in Kenya.

Mungo C, Adewumi K, Adoyo E, Zulu G, Goraya S, Ogollah C Front Oncol. 2024; 14:1360337.

PMID: 38532929 PMC: 10964769. DOI: 10.3389/fonc.2024.1360337.


Incorporating HPV 33 and cytology into HPV 16/18 screening may be feasible. A cross-sectional study.

Tatar B Arch Gynecol Obstet. 2022; 308(1):183-191.

PMID: 36512112 DOI: 10.1007/s00404-022-06876-8.


The Double Life-Saving Approach of Abdominal Radical Trachelectomy during Pregnancy for Early-Stage Cervical Cancer-An Overview of the Literature and Our Institutional Experience.

Stanca M, Ciobanu V, Gheorghe M, Kiss S, Cozlea A, Capilna M J Pers Med. 2021; 11(1).

PMID: 33466295 PMC: 7824800. DOI: 10.3390/jpm11010029.


The Preventive Effect of Dietary Antioxidants on Cervical Cancer Development.

Ono A, Koshiyama M, Nakagawa M, Watanabe Y, Ikuta E, Seki K Medicina (Kaunas). 2020; 56(11).

PMID: 33182663 PMC: 7698010. DOI: 10.3390/medicina56110604.


Characteristics and Treatments of Patients Aged 65 Years or Over with Cervical Cancer.

Xie S, Pan S, Zou S, Zhu H, Zhu X Clin Interv Aging. 2020; 15:841-851.

PMID: 32606624 PMC: 7293398. DOI: 10.2147/CIA.S255305.